Introduction
Three subtypes of ␣ 2 adrenergic receptors, termed A, B, C, are defined by differential affinities for antagonists including yohimbine, rauwolscine, prazosin and others (reviewed in Bylund et al). 1 All subtypes are expressed in major organ systems, 2 and they bind common medications including antihypertensives, diuretics, antiemetics, sedatives, anxiolytics and neuroleptics (reviewed in Maze and Tranquilli) . 3 Relative to other subtypes, ADRA2C expression predominates in heart, lung, Any G protein-coupled neurotransmitter receptor can be considered a reasonable candidate gene in schizophrenia. The high affinity binding of clozapine by the ADRA2C-higher than for any other known neurotransmitter receptor-was the main rationale for studying this gene in schizophrenics. 4 In addition, ADRA2C binds clonidine which is prescribed for Tourette's syndrome, 5 attention-deficient/hyperactivity disorder (ADHD), as well as hyperactivity associated with autism. 6, 7 Based on these clinical associations, structural variants of the ADRA2c gene were hypothesized to provide a sub-straight for genetic predisposition to psychiatric disease, but analysis of this gene was complicated by a high G+C content. This report communicates conditions for efficient amplification of ADRA2c gene segments and the genetic scanning of complete coding sequences and splice junctions under con-ditions that detect virtually all mutations in 104 schizophrenics, and pilot probes of patients with alcoholism (41 patients), cocaine abuse (25 patients), puerperal psychosis (30 patients), attention deficient/hyperactivity disorder (25 patients) and autism (25 patients) .
The focus of the manuscript is determination of the variation present in the ADRA2C receptor in patients of different ethnicity with schizophrenia, and pilot experiments with five other psychiatric diseases. The most notable finding is an in-frame deletion that is common in African-Americans.
Methods

Patient populations
Only the series of 104 Caucasian and African-American schizophrenics is intended as a thorough investigation of genetic variants predisposing to disease. Aside from schizophrenia, the sample collections represent pilot studies of common polymorphisms which might contribute to various psychiatric disorders. For each exploratory investigation, such as ADHD and autism, at least 50 alleles were examined. Power calculations based on the examination of 50 alleles indicate that we have 80% power to detect variants occurring at 3.2% allele frequency and 90% power to detect polymorphisms with 4.5% allele frequency.
Following identification of specific genetic variants within the complete collection, collaborators may conduct more extensive studies of allele frequencies in their full sample sets. Often these collections include large case-control studies, extended kindreds, sib-pair collections and so forth. In this case, JG is analyzing his studies of the TIDRU 1 variant within his complete series of substance abusers.
Genomic DNA samples from 250 patients were scanned for polymorphisms within the ADRA2C coding sequences. These patients included 104 schizophrenics, 41 alcoholics, 30 women with puerperal psychosis, 25 patients with ADHD, 25 cocaine abusers and 25 patients with autism. All schizophrenic patients met criteria for the disease defined by the Diagnostic and Statistical Manual, Third Edition, Revised (DSM-III-R), as described previously, 8 and most were ascertained through state mental institutions in Minnesota, Washington, and Oregon. Two schizophrenic patients from a Costa Rican population isolate 9 and two schizophrenic patients from a Finnish population isolate (personal communication: L Peltonen, Los Angeles) were also examined. Caucasian females who had experienced at least one episode of puerperal psychosis were recruited through the Division of Neuroscience at the University of Birmingham in the United Kingdom. 10 Finnish alcoholic patients were ascertained through collaborative efforts involving the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the University of Helsinki, Finland (by D Goldman, Rockville, MD, USA). Southwestern Native American patients with alcohol dependence were acquired through the NIAAA (by D Goldman), 11 and
Molecular Psychiatry patients with autism or ADHD were ascertained from the University of Chicago. 12, 13 Additional details of ethnic origins are shown in Table 1 .
Controls
Control samples came from patients seen at the Mayo Clinic in Rochester, Minnesota, for non-psychiatric complaints including heart disease, cancer, diabetes, and other general medical conditions. All were more than 40 years old and included 35 (26%) AfricanAmericans and 99 (74%) Caucasians.
PCR amplification and polymorphism analysis
The ADRA2C is an intronless gene with an average G+C content of 72% which rises to 90% in certain regions of the 1.4 kb coding sequence. The reference coding sequence was taken from Regan et al, 14 and supplemental upstream sequences came from GeneBank accession number U72648. Successful amplification required unusual conditions and was performed in two phases. A 1.8-kb segment containing all coding sequences was amplified (30 rounds), and then used as template for a second round of PCR* which amplified (30 rounds) all coding sequences in 15 over-lapping segments ranging from 125 to 300 nucleotides in length. Primer pairs for the 15 segments are listed using a nomenclature whereby the 5Ј nucleotide is identified according to the reference sequence and the length in 15 were modified by using 10% DMSO, annealing at an elevated temperature of 65°C, including P 33 -dATP (Amersham, Boston, MA, USA), and combining the use of two polymerases: 1.0 unit of Taq Gold (Perkin-Elmer-Roche, Norwalk, CT, USA) and 0.7 unit of High Fidelity Enzyme (BoehringerMannheim Biochemicals, GmbH, Germany) in 25 l reaction volume. Following PCR amplification, the 15 products from a single patient were pooled and electrophoresed on non-denaturing acrylamide gels by DOVAM-S (ie, (Detection Of Virtually All Mutations)-SSCP). DOVAM-S is an optimized form of SSCP with a generic set of conditions which has detected all of 180 different mutations and polymorphisms in three blinded analyses of the Factor VIII, Factor IX and ATM genes. 16, 17 DNA samples from 250 individuals with psychiatric disorders were screened by this method, *A 1.8 kb segment containing full coding sequences was produced by first round, external primers: ADRA2C(Hs)-5Ј-(233)-24D and ADRA2C(Hs)-3Ј(1571)-24U. This nomenclature 28 defines an oligonucleotide specific for the ␣ 2C adrenergic receptor (ADRA2C) in Homo sapiens (Hs) whose 5Ј base occurs at position −233 in the reference sequence;
14 the length of the primer is 24 nucleotides and the orientation is in the downstream direction (D). An in-frame deletion of 12 nucleotides removed four amino acids, Gly-Pro-Gly-Ala; the deleted bases are underlined: 5Ј-GACGGGCAGG GGGCGGGGCC GGGGGCGGCT GAG-3Ј. Note that the deleted nucleotides differ from the preceding 12 by only one base, and the four preceding amino acids are Gly-Gln-Gly-Ala. and PCR products with mobility shifts were re-amplified and sequenced with fluorescent dyes (PerkinElmer Model 377, Norwalk, CT, USA) to determine the nucleotide alteration. Nucleotide substitutions, deletions and insertions were confirmed by finding the same sequence in two independent PCR products and in sequencing tracings from both strands.
Genotypic analysis of one and two repeats of the Third Intracytoplasmic Domain Repeat Unit (TIDRU 1 and TIDRU 2 in control subjects
The frequency of the TIDRU 1 variant was determined among 35 African-American and 99 Caucasian controls who had no history of psychiatric disorder. This analysis was performed by PCR amplification and agarose gel electrophoresis of genomic DNA samples using PCR conditions described above, 18, 19 and the deletion variant was recognized by the appearance of smaller bands with accelerated mobility. Informative primer names 20 for this genotypic analysis are listed: ADRA2C(Hs)-(c898)-18D and ADRA2C(Hs)-(c1062)-20U. This nomenclature defines an oligonucleotide primer specific for the ADRA2C in Homo sapiens (Hs) whose 5Ј base occurs in Exon 1 at nucleotide number 898 in the reference sequence;
14 the length of the primer is 18 nucleotides and the orientation is in the downstream direction (D).
Results
Complete coding sequences and splice junctions were scanned for sequence variants in DNA samples from 250 patients with schizophrenia and several psychiatric disorders. Six sequence variants were discovered, including five silent single nucleotide substitutions and one in-frame deletion (ie, TIDRU 1 , see Table 1 and Figure 1 ). Sequence changes were found for all segments in which an unequivocal mobility shift occurred. No false negatives occurred.
TIDRU 1 is an in-frame deletion of 12 nucleotides which retains one of two 4-amino acid homologous repeats at codons 323-326. This deletion occurred commonly in 14 African-American patients (allele frequency 11/28, 39%), but it did not associate with schizophrenia since African-American controls had an allele frequency of 44% (31/70 alleles). Homozygous deletions occurred in two of 14 African-American schizophrenics and five of 25 African-American cocaine abusers, but none was detected in Caucasians (see Table 1 ). TIDRU 1 occurred much less commonly in 86 Caucasian schizophrenics of western European descent with an allele frequency of 3.5% which was similar to a 3.0% rate in 99 controls (control data not shown). Power calculations based on 86 cases and 99 controls and an allele frequency of 3.0% in controls indicate that we have 80% power to detect a relative risk of 3.8 with 95% confidence.
Five variants were single nucleotide substitutions (ie, two transitions and three transversions) which did not alter the amino acid sequence. G930C occurred in complete linkage disequilibrium with TIDRU 1 ; it was common among African-Americans (allele frequency of 44% (34/78)); and infrequent in other groups (3.6% (15/422) allele frequency). C408G and C1164T had allele frequencies of 1.2-2.0% in the full series of 250 patients, but the allele frequency increased to 25% of Finnish (two persons) and Costa Rican (two persons) schizophrenics and 14% of alcoholic Pima Indians (25 persons). C312A and C444T each occurred only twice in the series (0.4% allele frequency).
Discussion
Sensitive genetic analysis of all coding and splicing regions within 500 alleles detected six sequence variants-five silent nucleotide substitutions and one inframe deletion. Although the silent changes probably do not alter the receptor's function, TIDRU 1 (variable repeat) occurs in the third intracytoplasmic loop and may alter the therapeutic effects of clozapine or clonidine. The precedent for clinical effects comes from the V194G variant of the type 4 dopamine receptor (DRD4) which occurs in 12.5% of the African-Caribbean population and is less responsive to clozapine, dopamine and olanzapine by two orders of magnitude. 21 Since clozapine is an atypical neuroleptic used for treatmentresistant schizophrenics, differences in receptor-binding affinities could account for variations in clinical response. For example, this deletion polymorphism might account for some of the treatment-resistant cases Molecular Psychiatry of schizophrenia or confer a personality trait. There are further parallels with the DRD4 which has both high GC content and 1-10 iterations of a 48-base homologous sequence within the third intracytoplasmic loop. 22 Seven repeats in DRD4 are linked to ADHD, 23 and other variants may confer novelty-seeking behavior, 24 though the latter is controversial. 25 Based on the DRD4 similarities, it is possible that the ADRA2C deletion confers a personality trait and/or alters clinical response to clozapine. Finally, the ADRA2C also binds clonidine which is used to treat hypertension, Tourette's syndrome, 5 attentiondeficient/hyperactivity disorder, as well as hyperactivity associated with autism. 6, 7 Analysis of this deletion in African-American hypertensives may be particularly revealing because of the high frequency of both allele and disease in this population.
Two polymorphisms in the ADRA2B are similar to two ADRA2C variants. Like G930C and TIDRU 1 , the ADRA2B has an in-frame deletion of nine nucleotides occurring in linkage disequilibrium with a silent nucleotide substitution. 26 Further, the ADRA2B deletion removed one of three imperfect tandem repeats encoding three glutamate residues. Finally, the ADRA2B variants occurred within the third intracytoplasmic loop which is important for receptor-G protein coupling and agonist-promoted desensitization. These remarkable parallels hint that insertion/deletion within the third intracytoplasmic domain repeat units confers significant functional consequences which remain to be recognized. Regarding the origins of these sequence variants, the proximity (37 nucleotides) of G930C and TIDRU 1 suggests that they were produced by a single molecular event. This is consistent with recent data from a LacI mutagenesis animal model which found that double mutations occur approximately 600-fold more often than would be expected by chance alone. 27 The double mutations clustered and the distance between the double mutations decreased in an exponential manner, suggesting that doublet mutational events occur within a single cell cycle and may be caused by local mutational mechanisms such as polymerase error or nucleotide pool imbalance. 27 In summary, mutational analysis of the ADRA2C in 250 patients diagnosed with psychiatric disorders discovered an in-frame deletion, TIDRU 1 , linked to a silent nucleotide substitution, G930C, which occurred in approximately 40% of African-Americans and 3% of Caucasians. The deletion was not associated with schizophrenia in either population. Two other silent nucleotide changes (C408G and C1164T) may occur commonly in Finnish and Costa Rican schizophrenics and in alcoholic Pima Indians. Two additional silent nucleotide substitutions are uncommon. Additional studies are needed to determine whether TIDRU 1 confers a clinical phenotype.
